Exclusive license enables the development and commercialisation of 5hmC technologies for epigenetic biomarker discovery
Latest News from Cambridge Epigenetix
Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, today announces the formation of its Scientific Advisory Board (SAB). The SAB comprises experts for Cambridge Epigenetix’s key focus areas, including oncology, liquid biopsy and ageing.
Cambridge Epigenetix (CEGX) today announced the launch of its TrueMethyl® Whole Genome (TMWG) integrated workflow system for processing DNA samples
Cambridge Epigenetix is proud to sponsor the OXFORD GENOMICS FORUM Super Cool NGS Things & Funky Clinical Stuff on the 13th of July 2016 in Oxford.
Cambridge, UK – March 14, 2016 – Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, today announced the close of a $21 million Series B financing and the appointment of Dr. Geoff Smith as CEO.
CEGX will participate in the 1st Curie TechWatch Seminar on September 14th at the Institute Curie in Paris.
Exciting new study on DNA methylation and gene expression dynamics during spermatogonial stem cell differentiation in the early postnatal mouse testis
Researchers from Hiroyuki Sasaki’s lab published a breakthrough study on the regulation of spermatogonial stem cell formation and differentiation. Kubo et al. show distinct and dynamic regulation of DNA methylation during spermatogonial stem cell formation and differentiation in the neonatal and early postnatal testes. Using TrueMethyhl® oxidative bisulfite-Seq they further revealed a unique accumulation and distribution of non-CG methylation and 5hmC marks in neonatal prospermatogonia.
In a recent study published in Nature Chemical Biology, researchers at University of Cambridge, the Babraham Institute and the University of Bath in the UK, show that 5-Formylcytosine (5fC) can be a stable epigenetic modification in mammalian cells. Their finding is a further step stone in elucidating the various biological implications of epigenetic DNA modifications.
Cambridge Epigenetix is proud to sponsor the first Oxford Transcription and Chromatin Meeting. The event took place on June 15th and 16th at Oxford Martin School and brought together Oxford researchers for two exciting days of seminars, scientific discussions and networking.
New Nature Neuroscience paper from researhers at The Mount Sinai Hospital used TrueMethyl oxBS-Seq to confirm a role for TET and DNA hydroxymethylation cocaine action.